MGMT and central nervous system cancer: Low-intensity fluorescence ultrasound (LIFU) was employed to deliver a liposomal O6-(4-bromothenyl) guanine (O6BTG) derivative that inactivates MGMT in a mouse model with temozolomide-resistant glioma [53].